Shalby Ltd. · NSE:SHALBY
Shalby — Q1 FY2027 Earnings Presentation
42 slides from Shalby's earnings presentation, Aug 12, 2026
Slide 1: Exchange filing cover letter for investor presentation
Shalby/SE/2026‐27/39 August 12, 2026 The Listing Department Corporate Service Department National Stock Exchange of India Ltd BSE Limited Mumbai 400 051. Mumbai 400 001. Scrip Code : SHALBY Scrip Code: 540797 Through : https://neaps.nseindia.com/NEWLISTINGCORP/ Through : http://listing.bseindia.com
Slide 2: Investor Presentation Q1 FY2027
Investor Presentation Q1 FY2027
Slide 3: Disclaimer
DISCLAIMER This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful. This pr
Slide 4: Agenda
AGENDA 01 GROUP QUARTERLY SHALBY CONSOLIDATED AND ANNUAL QUARTERLY PERFORMANCE PERFORMANCE 02 HOSPITAL SHALBY BUSINESS QUARTERLY STANDALONE QUARTERLYAND ANNUAL PERFORMANCE PERFORMANCE 03 SHALBY INTERNATIONAL QUARTERLY PERFORMANCE 04 SHALBY MEDTECH QUARTERLY PERFORMANCE 05 ABOUT SHALBY LIMITED 3
Slide 5: Financials Snapshot Q1 FY27
Financials Snapshot Q1 FY27 Consolidated Total Revenue at ₹ 3,386 mn in Q1 FY27 vs ₹ 3,034 mn in Q1 FY26 Consolidated EBITDA at ₹ 490 mn in Q1 FY27 vs ₹ 485 mn in Q1 FY26 Consolidated Consolidated PBT at ₹ 197 mn in Q1 FY27 vs ₹ 227 mn in Q1 FY26 Financial Highlights Consolidated PAT at ₹ 105 mn in
Slide 6: Consolidated Performance Highlights – Q1 FY27
Consolidated Performance Highlights – Q1 FY27 Financial Performance (in INR Mn) Total Revenue EBITDA1 & Margin 3386 3034 2955 485 490 374 16.0% 12.7% 14.5% Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Up 11.6% Up 0.9% PBT & Margin PAT & Margin 227 197 185 96 105 77 7.5% 3.3% 5.8% 6.2% 3.1% 2.5% Q
Slide 7: Consolidated P/L & B/S – Q1 FY27
Consolidated P/L & B/S – Q1 FY27 Profit & Loss Balance Sheet (INR Mn) Q1 Q4 Q1 Q-o-Q Y-o-Y Gross 5509 Particulars (INR Mn) Borrowings FY27 FY26 FY26 Growth Growth Total Revenue 3386 2955 3034 14.6% 11.6% Cash & Cash 873 Equivalents EBITDA2 490 374 485 30.9% 0.9% Net Cash/(Debt) (4636) EBITDA Margin
Slide 8: Consolidated Revenue & EBITDA Breakup – Q1 FY27
Shalby Limited : Consolidated Revenue & EBITDA Breakup – Q1 FY27 Revenue (%) Revenue (in INR Mn) EBITDA (in INR Mn) Shalby Hospitals, 78.32% 2652.2 450.5 Pharma & Franchise1 Shalby International (PK Healthcare, 7.75% 39.2 262.3 Delhi-NCR) 2 Shalby MedTech 13.92% 471.7 1.6 (Implant Business) Others 0
Slide 9: Financial Trends – Shalby Limited (Consolidated)
Financial Trends – Shalby Limited (Consolidated) Total Revenue (In INR Crs) EBITDA (In INR Crs) & Margin (%) 1168 1115 196 953 170 827 159 160 711 132 440 95 22% 19% 19% 21% 14% 15% FY21 FY22 FY23 FY24 FY25 FY26 FY21 FY22 FY23 FY24 FY25 FY26 ROCE (%) 14% 13% 11% 8% 8% 7% FY21 FY22 FY23 FY24 FY25 FY2
Slide 10: Shalby Limited Business Verticals
SHALBY LIMITED BUSINESS VERTICALS www.shalby.org
Slide 11: A Legend and Visionary Doctorpreneur behind Shalby
A Legend and Visionary Doctorpreneur behind Shalby Dr Vikram I. Shah, the Founder of Shalby Ltd, is a world-renowned Joint Replacement Surgeon who innovated the “Zero Technique” that revolutionized Joint Replacement Surgery. A visionary entrepreneur, he transformed Shalby from a 6-bedded hospital in
Slide 12: Standalone Business Performance
STANDALONE BUSINESS PERFORMANCE 11
Slide 13: Standalone Business Highlights – Q1 FY27
Standalone Business Highlights – Q1 FY27 Financial Performance (in INR Mn) Total Revenue EBITDA1 & Margin 524 2591 478 2422 2304 371 21.6% 16.1% 18.4% Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Up 7.0% Down 8.8% PBT & Margin PAT & Margin 401 537 339 235 257 251 16.6% 10.2% 13.1% 10.6% 23.3% 9.7
Slide 14: Standalone Business P&L and B/S – Q1 FY27
Standalone Business P&L and B/S – Q1 FY27 Profit & Loss Total Revenue to EBITDA Q1 Q4 Q1 QoQ YoY Particulars (INR Mn) FY27 FY26 FY26 Growth Growth 6.3% 7.1% Other expenses 11.1% 11.5% Total Revenue 2591 2304 2422 12.4% 7.0% 8.6% 7.7% Employee Benefit Expenses 25.9% 27.4% Other Operative EBITDA2 478
Slide 15: Shalby International Q1'FY27 Highlights
Shalby International Q1’FY27 Highlights IP Count Total 18900+ ARPOB 1200+ Employees Patients Total ₹91,326 Expertise in 240+ Served in Revenue of 42% Liver, Doctors & FY25-26 ₹262.3 Mn. OP Count revenue Kidney, generated Total Bed Consultant in Q1’FY27 ALOS 3.80 4650+ Blood & 45+ from Capacity 130 1
Slide 16: Shalby International Performance Highlights – Q1 FY27
Shalby International Performance Highlights – Q1 FY27 Revenue (INR MN) EBITDA (INR MN) 262.29 232.50 18.17 (31.76) Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 PBT (INR MN) PAT (INR MN) (39.78) (39.78) (97.56) (97.56) Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 15 1. EBITDA includes other income
Slide 17: Hospital Business Highlights Q1 FY27
Hospital Business Highlights Q1 FY27 Surgery Count and YoY Performance Operational Performance3 Q1 Q1 YoY Particulars FY27 FY26 Growth Arthroplasty Orthopaedic In-Patient1 (Nos.) 23,895 22,499 6.2% 3830+ 9.2% 1420+ 5.0% Out Patient (Nos.) 1,28,139 1,34,122 (4.5%) Surgeries Count 9,326 9,013 3.5% Onc
Slide 18: Hospital Business Highlights: Speciality Revenue Mix
Hospital Business Highlights Speciality Revenue Mix Q1 FY2026 2 Q1 FY2027 2 General Others Surgery, General Others Surgery, 6% 7% Surgery, 6% Surgery, 7% Arthroplasty, 41% Arthroplasty, Nephrology, 35% 5% Nephrology, 6% Neurology, 5% Neurology, 6% Orthopaedic Orthopaedic, , 10% 11% Critical Care & G
Slide 19: Hospital Business Highlights: Payor Mix
Hospital Business Highlights Payor Mix Q1 FY20261 Q1 FY20271 Government, Self Pay, 36% Self Pay, 30% 24% Government, 32% TPA/Insurance, 40% TPA/Insurance, 38% Notes: 18 1. Q1’FY26 & Q1’FY27 numbers include PK Healthcare performance.
Slide 20: Maturity Wise Hospital Performance – Q1 FY27
Maturity Wise Hospital Performance – Q1 FY271 EBITDA EBITDA No. of Total Revenue Operational Maturity ARPOB (in INR Mn) Margin Hospitals (in INR Mn) Beds (in%) 10+ Years 7 1612.2 808 48,880 371.0 23.0% 5-10 3 927.9 427 33,197 161.3 17.4% Years 0-5 1 262.3 130 91,326 18.2 6.9% Years Corporate2,3 - 50
Slide 21: Financial Trends – Standalone Business
Financial Trends – Standalone Business 1 Total Revenue (In INR Cr) EBITDA (In INR Cr) & Margin (%) 900 923 850 198 727 186 660 162 170 143 428 96 22% 22% 22% 23% 21% 18% FY21 FY22 FY23 FY24 FY25 FY26 FY21 FY22 FY23 FY24 FY25 FY26 PAT (In INR Cr) & Margin (%) ROCE (%) 18% 16% 113 14% 14% 104 11% 81 8
Slide 22: Operational Trends – Hospital Business
Operational Trends – Hospital Business 1,2 Bed Capacity Operational Beds Occupied Beds 1390 1415 633 659 646 2297 1365 2267 2242 1235 1260 563 570 1164 2137 428 2112 2012 FY21 FY22 FY23 FY24 FY25 FY26 FY21 FY22 FY23 FY24 FY25 FY26 FY21 FY22 FY23 FY24 FY25 FY26 Total Surgeries Count ARPOB (in INR) AL
Slide 23: Key Focus Areas For Future In Hospital business
Key Focus Areas For Future In Hospital business Global Leader in Joint Replacement with diversification in other specialties • Continue to maintain global leadership in joint replacements • Ongoing diversification with Cardiac Science, Oncology, Neuro-science, Critical Care, General Medicine and Tra
Slide 24: Implant Business
SHALBY Global Technologies Pte. Ltd. 2 SAT ind ovine ives. Put. Ltd
Slide 25: Shalby's Company Structure of Implant Business
Shalby’s Company Structure of Implant Business SHALBY LIMITED Shalby MedTech Limited (SMTL)* Shalby Advanced Shalby Global Shalby Advanced Technologies Technologies Pte Technologies Inc.(SAT) Ltd (SGT) (India) Pvt. Ltd. 24 * Shalby MedTech Limited (SMTL) formerly known as Mars Medical Devices Limite
Slide 26: Shalby MedTech Performance Highlights: Q1 FY27
Shalby MedTech Performance Highlights: Q1 FY27 Financial Performance (in INR Mn) Total Revenue Total EBITDA SMTL SAT, SGTPL SMTL SMTL SAT, Inc. SGTPL SMTL Inc. Consol. Consol. Q1 FY26 182.44 302.06 3.64 308.25 Q1 FY26 12.79 (18.12) (2.27) (7.48) Q4 FY26 280.89 326.03 12.88 402.68 Q4 FY26 10.12 146.0
Slide 27: Shalby MedTech Financial Historical Trend
Shalby MedTech Financial Historical Trend Financial Performance (in INR Mn) Total Revenue Total EBITDA SMTL SAT, Inc. SGTPL SMTL Consol. SMTL SAT, Inc. SGTPL SMTL Consol. FY 24 156.74 786.02 14.49 584.41 FY 24 (17.25) 1.18 (8.00) (48.52) FY 25 352.04 1,081.82 63.72 922.86 FY 25 (116.76) (77.92) 9.91
Slide 28: Shalby MedTech Consolidated Inventory
Shalby MedTech Consolidated Inventory SMT Consolidated Inventory (in INR mn) 3,454 3,374 2,914 2,534 2,452 2,106 2,028 1,562 1,315 1,350 1,153 934 923 886 920 922 651 584 544 472 Days of Inventory to Sales Consol. Total Revenue Consol. Total Inventory FG RM+WIP (in Days) Q1 FY27 651 472 3,374 2,452
Slide 29: Core Strategic Pillars
CORE STRATEGIC PILLARS ▪ Recruitment, retention & Portfolio ▪ Continual training of training of sales and & employees, HCPs and corporate teams. Innovation Channel Partners. ▪ Strong employee ▪ Solid Partner engagement, involvement Relationship. and regular Supply People Customer ❖ Employees communi
Slide 30: Implant Business Footprint Global
Implant Business Footprint Global Existing Markets • North America • Japan • India • Indonesia Approval Received • Malaysia (Knee) • Vietnam (Hip) • Nepal • Burma • Brunei Upcoming Markets • Argentina • Peru • Colombia • Iran • Iraq • Paraguay 29
Slide 31: Implant Business Footprint Across India
Implant Business Footprint Across India Existing Markets • Andhra Pradesh • Chhattisgarh • Gujarat • Haryana • Karnataka • Madhya Pradesh • Maharashtra • Punjab • Rajasthan • Tamil Nadu • Telangana • West Bengal Upcoming Markets • Assam • Odisha • Uttar Pradesh • Uttarakhand 30
Slide 32: Marketing Engagements Building Momentum Early in the Quarter
Marketing Engagements EV ENT HI GHL I GHTS · AP RI L – MAY 2 0 2 6 Building Momentum Early in the Quarter 5–6 APR 2026 5 APR 2026 23–24 MAY 2026 National Sales Kick-Off · Jaipur BOSCON 2026 DAA Workshop · Bengaluru Brought together sales and leadership teams Connected with leading orthopedic surgeon
Slide 33: Marketing Engagements: Deepening Surgeon Engagement
Marketing Engagements EVENT HIGHLIGHTS · JUNE – AUGUST 2026 Deepening Surgeon Engagement 14–15 JUN 2026 28 JUN 2026 31 JUL – 2 AUG 2026 Guwahati Knee Course Ahmedabad Orthopaedic Society Delhi Conference Conference A 2-day program bringing together leading Participated in “Fracta Vincimus,” featurin
Slide 34: About Shalby Limited
ABOUT SHALBY LIMITED -Passion=Compassion-Innovation- 33
Slide 35: Shalby At A Glance
Shalby At A Glance OPD clinics Presence 13 60 23 Orthopedic Implant Hospitals1 Domestic International2 Manufacturing in USA 32 Strength 2,200+ 4,500+ 1,150+ Years of Legacy Bed Capacity Total Employees3 Doctors4 Team Clinical Excellence #1 30+ ~3.5 million+ 175,000+ Global Ranking in Specialties Pat
Slide 36: 32 Years of ELITE Legacy
32 Years of ELITE Legacy Integrity Highest standards of transparency accountability, and corporate governance Learning Team-Work Laser sharp focus on A patient-centric focused upgrading the skills of team with a great blend of our team and building experience, diversity, fresh people capability thin
Slide 37: Our Journey & Expansion Plan
Our Journey & Expansion Plan • Jaipur Shalby, Jaipur (237 beds) • Naroda Shalby, Ahmedabad (267 beds) Vijay Shalby, Ahmedabad • Vapi Shalby, Vapi (146 beds) • • Surat Shalby, Surat (243 beds) 27 beds • Asha Parekh • Krishna Shalby, Ahmedabad (220 • Zynova1 Shalby, Mumbai (100 beds) • Gwalior1 SOCE,
Slide 38: Hospitals Portfolio
Hospitals Portfolio Multispecialty Hospital Units SG Shalby Vapi Shalby Indore Shalby Jaipur Shalby Krishna Shalby Mohali Shalby Naroda Shalby Jabalpur Shalby Surat Shalby Shalby International 37
Slide 39: Biggest Healthcare Corporate Group in Western and Central India
BIGGEST HEALTHCARE CORPORATE GROUP IN WESTERN AND CENTRAL INDIA Domestic Presence PUNJAB ▪ Mohali – 145 beds DELHI ▪ Gurugram – 130 beds RAJASTHAN ▪ Jaipur – 237 beds GUJARAT ▪ Ahmedabad o SG – 201 beds o Krishna – 220 beds o Naroda – 267 beds o Vijay – 27 beds ▪ Vapi – 146 beds ▪ Surat – 243 beds M
Slide 40: Shalby Limited Shareholding Pattern (as on 30th June'26)
Shalby Limited Shareholding Pattern (as on 30th June’26) Employee Benefit Trust, 0.65% Public , 20.26% DIIs, 0.30% FIIs, 4.47% Promoters, 74.33% Promoters FIIs DIIs Public Employee Benefit Trust 39
Slide 41: Experienced Board Of Directors
Experienced Board Of Directors Dr. Ashok Bhatia Mr. Tej Malhotra Ms. Sujana Shah Independent Independent Independent Director Director Director Mr. Ashok Bhatia is an experienced Pharmaceutical Mr. Malhotra comes with over four decades of Mrs. Sujana Shah, a practicing Chartered Accountant executive
Slide 42: Thank You
Thank You For further information, please contact: Jigar Todi Investors Relation & Corporate Strategist +91 9512049871 ircs3.corp@shalby.org SHALBY LIMITED I Regd Off: Opp. Karnavati Club, S.G. Road, Ahmedabad – 380015, Gujarat, India. Phone: 079 4020 3000 Fax: +91 79 4020 3109 | Website: www.shalby